Abstract
The first antidepressant drugs- were detected by serendipity in clinical trials. Iproniazid was developed for the treatment of tuberculosis. The observation of mood-elevating effects was followed by the detection of the inhibition of the enzyme monoamine oxidase. During clinical investigation of phenothiazine analogues as neuroleptics, imipramine was found to be relatively ineffective in agitated psychotic patients but showed remarkable benefit in depressed patients. Later on, inhibition of uptake of biogenic amines was found to be the main mechanism of action resulting in downregulation of β-receptors (Vetulani et al. 1976). Influence on α 2-adrenoreceptors (Johnson et al. 1980) was discussed as well. Several lines of preclinical and clinical evidence indicate that an enhancement of 5-HTmediated neurotransmission might underlie the therapeutic effect of most antidepressant treatments (Blier and de Montigny 1994).
This is a preview of subscription content, log in via an institution to check access.
References and Further Reading
General Considerations
Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220–226
Chen G (1964) Antidepressives, analeptics and appetite suppressants. In: Laurence DR, Bacharach AL (eds) Evaluation of drug activities: pharmacometrics. Academic, London/New York, pp 239–260
Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and further needs. Trends Pharmacol Sci 23:238–245
Johnson RW, Reisine T, Spotnitz S, Weich N, Ursillo R, Yamamura HI (1980) Effects of desipramine and yohimbine on a α 2- and β-adrenoreceptor sensitivity. Eur J Pharmacol 67:123–127
Kuhn R (1958) The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 115:459–464
Panksepp J, Yates G, Ikemoto S, Nelson E (1991) Simple ethological models of depression: socialisolation induced despair in chicks and mice. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 161–181
Porsolt RD, Lenègre A, McArthur RA (1991) Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 137–159
Vetulani J, Stawarz RJ, Dingell JV, Sulser F (1976) A possible common mechanism of action of antidepressant treatments: reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn Schmiedebergs Arch Pharmacol 293:109–114
Willner P, Muscat R (1991) Animals models for investigating the symptoms of depression and the mechanisms of action of anti-depressant drugs. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 183–198
Inhibition of [3H]-Norepinephrine Uptake in Rat Brain Synaptosomes
Coyle JT, Snyder SH (1969) Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J Pharmacol Exp Ther 170:221–231
Hertting G, Axelrod J (1961) Fate of tritiated noradrenaline at the sympathetic nerve endings. Nature 192:172–173
Iversen LL (1975) Uptake mechanisms for neurotransmitter amines. Biochem Pharmacol 23:1927–1935
Lippmann W, Pugsley TA (1977) Effects of 3,4-dihydro-1H-1,4-oxazino[4,3-a]indoles, potential antidepressants, on biogenic amine uptake mechanisms and related activities. Arch Int Pharmacodyn 227:324–342
Morin D, Zini R, Urien S, Tillement JP (1989) Pharmacological profile of Binedaline, a new antidepressant drug. J Pharmacol Exp Ther 249:288–296
Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350:350–354
Schloss P, Mayser W, Betz H (1992) Neurotransmitter transporters. A novel family of integral plasma membrane proteins. FEBS Lett 307:76–80
Snyder SH, Coyle JT (1969) Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther 165:78–86
Tehani-Butt SM (1992) [3H]Nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 260:427–436
Inhibition of [3H]-Dopamine Uptake in Rat Striatal Synaptosomes
Altar CA, Marshall JF (1987) Neostriatal dopamine uptake and reversal of age-related movement disorders with dopamineuptake inhibitors. Ann N Y Acad Sci 515:343–353
Carroll FI, Gao Y, Abraham P, Lewin AH, Lew R, Patel A, Boja JW, Kuhar MJ (1992) Probes for the cocaine receptor. Potentially irreversible ligands for the dopamine transporter. J Med Chem 35:1814–1817
Cline EJ, Scheffel U, Boja JW, Carroll FI, Katz JL, Kuhar MJ (1992) Behavioral effects of novel cocaine analogs: a comparison with in vivo receptor binding potency. J Pharmacol Exp Ther 260:1174–1179
Cooper BR, Hester TJ, Maxwell RA (1980) Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence of selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215:127–134
Elsworth JD, Taylor JR, Berger P, Roth RH (1993) Cocainesensitive and -insensitive dopamine uptake in prefrontal cortex, nucleus accumbens and striatum. Neurochem Int 23:61–69
Giros B, El Mestikawi S, Bertrand L, Caron MG (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 295:149–153
Giros B, El Mestikawi S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42:383–390
Heikkila RE, Orlansky H, Cohen G (1975) Studies on the distinction between uptake inhibition and release of [3H]dopamine in rat brain slices. Biochem Pharmacol 24:847–852
Horn AS, Coyle JT, Snyder SH (1970) Catecholamine uptake by synaptosomes from rat brain: structure-activity relationships of drugs with different effects on dopamine and norepinephrine neurons. Mol Pharmacol 7:66–80
Hunt P, Raynaud J-P, Leven M, Schacht U (1979) Dopamine uptake inhibitors and releasing agents differentiated by the use of synaptosomes and field-stimulated brain slices in vitro. Biochem Pharmacol 28:2011–2016
Kilty JE, Lorang D, Amara SG (1991) Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254:578–579
Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, Al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL, Milius RA, Wang S, Smith EO, Roth RH, Charney DS, Hoffer PB, Innis RB (1993) SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13:295–309
Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA (1989) Cocaine receptors labeled by [3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharmacol 36:518–524
Michel MC, Rother A, Hiemke C, Ghraf R (1987) Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. Biochem Pharmacol 36:3175–3180
Nakachi N, Kiuchi Y, Inagaki M, Inazu M, Yamazaki Y, Oguchi K (1995) Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. Eur J Pharmacol 281:195–203
Reith MEA, de Costa B, Rice KC, Jacobson AE (1992) Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol 227:417–425
Richfield AK (1991) Quantitative autoradiography of the dopamine uptake complex in rats brain using [3H]GBR 12935-binding characteristics. Brain Res 540:1–13
Rothman RB, Grieg N, Kim A, de Costa BR, Rice KC, Carroll FI, Pert A (1992) Cocaine and GBR 12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacol Biochem Behav 43:1135–1142
Saijoh K, Fujiwara H, Tanaka C (1985) Influence of hypoxia on release and uptake of neurotransmitters in guinea pig striatal slices: dopamine and acetylcholine. Jpn J Pharmacol 39:529–539
Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P, Kuhar M, Uhl G (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254:576–578
Snyder SH, Coyle JT (1969) Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther 165:78–86
Tuomisto L, Tuomisto J (1974) Dopamine uptake in striatal and hypothalamic synaptosomes: conformational selectivity of the inhibition. Eur J Pharmacol 25:351–361
Usdin RB, Mezey E, Chen C, Brownstein MJ, Hoffman BJ (1991) Cloning of the cocaine-sensitive bovine dopamine transporter. Proc Natl Acad Sci U S A 88:11168–11171
Inhibition of [3H]-Serotonin Uptake
Åsberg M, Mårtensson B (1993) Serotonin selective antidepressant drugs: past, present, future. Clin Neuropharmacol 16(Suppl 3):S32–S44
Åsberg M, Thoren P, Traskman L, Bertillson L, Ringberger V (1975) “Serotonin depression” – a biochemical subgroup with in the affective disorders. Science 191:478–480
Biegon A, Mathis C (1993) Evaluation of [3H]paroxetine as an in vivo ligand for serotonin uptake sites: a quantitative autoradiographic study in the rat brain. Synapse 13:1–9
Blakely RD, Berson HE, Fremeau RT, Caron MG, Peek MM, Prince HK, Bradley CC (1991) Cloning and expression of a functional serotonin transporter from rat brain. Nature 354:66–70
Blier P, de Montigny C (1997) Current psychiatric uses of drugs acting on the serotonin system. In: Baumgarten HG, Göthert M (eds) Serotoninergic neurons and 5-HT receptors in the CNS, vol 129, Handbook of experimental pharmacology. Springer, Berlin/Heidelberg, pp 727–750
Brøsen K, Narajo CA (2001) Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 11:275–283
Chen F, Larsen MB, Sánchez C, Wiborg O (2005) The Senatiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 15:193–198
Cheng CHK, Costall B, Naylor RJ, Rudd JA (1993) The effect of 5-HT receptor ligands on the uptake of [3H]-5-HT into rat cortical synaptosomes. Eur J Pharmacol 239:211–214
D’Amato RJ, Largent BL, Snowman AM, Snyder SH (1987) Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther 242:364–371
de Montigy C (1980) Enhancement of 5-HT neurotransmission by antidepressant treatment. J Physiol Paris 77:455–461
Fray MJ, Bish G, Brown AD, Fish PV, Stobie A, Wakenhut F, Whitlok GA (2006) N-(1,2-Diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem 16:4345–4348
Fuller RW (1990) Drugs affecting serotonin neurones. Prog Drug Res 35:85–108
Fuller RW (1993) Biogenic amine transporters. Neurotransmissions 9(2):1–4
Fuller RW, Wong DT (1990) Serotonin uptake and serotonin uptake inhibition. Ann N Y Acad Sci 600:68–80
Gershon MD, Miller Jonakait G (1979) Uptake and release of 5-hydroxytryptamine by enteric 5-hydroxytryptaminergic neurons: effects of fluoxetine (Lilly 110140) and chlorimipramine. Br J Pharmacol 66:7–9
Grimsley SR, Jahn MW (1992) Paroxetine, sertaline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 11:930–957
Hallstrom COS, Rees WL, Pare CMB, Trenchard A, Turner P (1976) Platelet uptake of 5-hydroxytryptamine and dopamine in depression. Postgrad Med J 52(Suppl 3):40–44
Hatanaka K, Nomura T, Hidaka K, Takeuchi H, Yatsugi S, Fujll M, Yamaguchi T (1996) Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity. Neuropharmacology 35:1621–1626
Hoffman BJ, Mezey E, Brownstein MJ (1991) Cloning of a serotonin transporter affected by antidepressants. Science 254:579–580
Horn AS (1973) Structure-activity relations for the inhibition of 5-HT uptake into rat hypothalamic homogenates by serotonin and tryptamine analogues. J Neurochem 21:883–888
Horn AS, Trace RCAM (1974) Structure-activity relations for the inhibition of 5-hydroxytryptamine uptake by tricyclic anti-depressants into synaptosomes from serotoninergic neurons in rat brain homogenates. Br J Pharmacol 51:399–403
Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 9(Suppl 1):19–26
Hyttel J, Larsen JJ (1985) Serotonin-selective antidepressants. Acta Pharmacol Toxicol 56(Suppl 1):146–153
Keane PE, Soubrié P (1997) Animal models of integrated serotoninergic functions: their predictive value for the clinical applicability of drugs interfering with serotoninergic transmission. In: Baumgarten HG, Göthert M (eds) Serotoninergic neurons and 5-HT receptors in the CNS, vol 129, Handbook of experimental pharmacology. Springer, Berlin/Heidelberg, pp 709–725
Koe BK, Weissman A, Welch WM, Browne RG (1983) Sertaline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 226:686–700
Langer SZ, Moret C, Raisman R, Dubocovich ML, Briley M (1980) High-affinity [3H]imipramine binding in rat hypothalamus: association with uptake of serotonin but not of epinephrine. Science 210:1133–1135
Luo H, Richardson JS (1993) A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants. Int Clin Psychopharmacol 8:3–12
Marcusson JO, Norinder U, Högberg T, Ross SB (1992) Inhibition of [3H]paroxetine binding by various serotonin uptake inhibitors. Eur J Pharmacol 215:191–198
Mennini T, Mocaer E, Garattini S (1987) Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedebergs Arch Pharmacol 336:478–482
Murdoch D, Keam SJ (2005) Escitalopram. A review of its use in the management of major depressive disorder. Drugs 65:2379–2404
Ögren SO, Ross SB, Holm AC, Renyi AL (1981) The pharmacology of zimelidine: a 5-HT selective reuptake inhibitor. Acta Psychiatr Scand 290:127–151
Pacher P, Kohegyi E, Kecskemeti V, Furst S (2001) Current trends in the development of new antidepressants. Curr Med Chem 8:89–100
Ross SB (1980) Neuronal transport of 5-hydroxytryptamine. Pharmacology 21:123–131
Sánchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O (2003) Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in anima models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 167:353–362
Scatton B, Claustre Y, Graham D, Dennis T, Serrano A, Arbilla S, Pimoule C, Schoemaker H, Bigg D, Langer SZ (1988) SL 81.0385: a novel selective and potent serotonin uptake inhibitor. Drug Dev Res 12:29–40
Shank RP, Vaught JL, Pelley KA, Setler PE, McComsey DF, Maryanoff BE (1988) McN-5652: a highly potent inhibitor of serotonin uptake. J Pharmacol Exp Ther 247:1032–1038
Shaskan EG, Snyder SH (1970) Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. J Pharmacol Exp Ther 175:404–418
Tordera RM, Monge A, del Rio J, Lasheras B (2002) Antidepressant-like activity of VN2222. A serotonin reuptake inhibitor with high affinity at 5-HT1A receptors. Eur J Pharmacol 442:63–71
Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR (1992) Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1Dα and 5-HT1Dβ. Proc Natl Acad Sci U S A 89:3630–3634
Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushiski JH, Robertson DW (1993) Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 8:337–344
Binding to Monoamine Transporters
Fleckenstein AE, Haughey HM, Metzger RR, Kokoshka JM, Riddle EL, Hanson JE, Gibb JW, Hanson GR (1999) Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol 382:45–49
Gu H, Wall SC, Rudnick G (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics and ion dependence. J Biol Chem 269:7124–7130
Inazu M, Kubota N, Takeda H, Zhang J, Kiuchi Y, Oguchi K, Matsumiya T (1999) Pharmacological characterization of dopamine transport in cultured rat astrocytes. Life Sci 664:2239–2245
Jayanthi LD, Prasad PD, Ramamoorthy S, Mahesh VB, Leibach FH, Ganapahy V (1993) Sodium- and chloride-dependent, cocaine-sensitive, high-affinity binding of nisoxetine to the human placenta norepinephrine transporter. Biochemistry 32:12178–12185
Leonard BE (2000) Evidence for a biochemical lesion in depression. J Clin Psychiatry 61(Suppl 6):12–17
Madras BK, Pristupa ZB, Nizmik HB, Liang AY, Blundell P, Gonzalez MD, Meltzer PC (1996) Nitrogen-based drugs are not essential for blockade of monoamine transporters. Synapse 24:340–348
Meltzer PC, Liang AY, Blundell P, Gonzalez MD, Chen Z, George C, Madras BK (1997) 2-carbomethoxy-3-aryl-8- oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters. J Med Chem 40:2661–2673
Munson PJ, Rodbard D (1980) LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220–239
Murphy DL, Wichems C, Li Q, Heils A (1999) Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Trends Pharmacol Sci 20:246–252
Nelson N (1998) The family of Na+/Cl- neurotransmitter transporters. J Neurochem 71:1785–1803
O’Riordan C, Phillips OM, Williams DC (1990) Two affinity states for [3H]imipramine binding to the human platelet 5- hydroxytryptamine carrier: an explanation for the a Uosteric interaction between hydroxytryptamine and imipramine. J Neurochem 54:1275–1280
Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305–1322
Pfenning MA, Richelson E (1990) Methods for studying receptors with cultured cells of nervous tissue origin. In: Yamamura HI, Enna SJ, Kuhar MJ (eds) Methods in neurotransmitter receptor analysis. Raven, New York, pp 147–175
Pristupa ZB, Wilson JM, Hoffman BJ, Kish SJ, Niznik HB (1994) Pharmacological heterogeneity of the cloned an native human dopamine transporter: dissociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol 45:125–135
Sato T, Kitayama S, Mitsuhata C, Ikeda T, Morita K, Dohi T (2000) Selective inhibition of monoamine neurotransmitter transporters by synthetic local anesthetics. Naunyn Schmiedebergs Arch Pharmacol 361:214–220
Siebert GA, Pond SM, Bryan-Lluka LJ (2000) Further characterisation of the interaction of haloperidol metabolites with neurotransmitter transporters in rat neuronal cultures and in transfected COS-7 cells. Naunyn Schmiedebergs Arch Pharmacol 361:255–264
Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249–258
Tatsumi M, Jansen K, Blakely RD, Richelson E (1999) Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 368:277–283
Antagonism of p-Chloramphetamine Toxicity by Inhibitors of Serotonin Uptake
Fuller RW, Snoddy HD, Perry KW, Bymaster FP, Wong DT (1978) Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin – comparison of fluoxetine and chlorimipramine. Biochem Pharmacol 27:193–198
Harvey JA, McMaster SE, Yunger LM (1975) p-Chloramphetamine: selective neurotoxic action in brain. Science 187:841–843
Meek JL, Fuxe K, Carlsson A (1971) Blockade of p-chloromethamphetamine induced 5-hydroxytryptamine depletion by chlorimipramine, chlorpheniramine and meperidine. Biochem Pharmacol 20:707–709
Sekerke HJ, Smith HE, Bushing JA, Sanders-Busch E (1975) Correlation between brain levels and biochemical effects of the optical isomers of p-chloroamphetamine. J Pharmacol Exp Ther 193:835–844
Squires R (1972) Antagonism of p-chloramphetamine (PCA) induced depletion of 5-HT from rat brain by some thymoleptics and other psychotropic drugs. Acta Pharmacol Toxicol 31:35
Receptor Subsensitivity After Treatment with Antidepressants: Simultaneous Determination of the Effect of Chronic Anti-depressant Treatment on β-adrenergic and 5-HT2 Receptor Densities in Rat Cerebral Cortex
Banerjee SP, Kung SL, Riggi SJ, Chanda SK (1977) Development of β-adrenergic receptor subsensitivity by antidepressants. Nature 268:455–456
Bergstrom DA, Kellar KJ (1979) Adrenergic and serotoninergic receptor binding in rat brain after chronic desmethylimipramine treatment. J Pharmacol Exp Ther 209:256–261
Blackshear MA, Sanders-Bush E (1982) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 221:303–308
Bucket WR, Thomas PC, Luscombe GP (1988) The pharmacology of sibutramine hydrochloride (BTS 54524), a new anti-depressant which induces rapid noradrenergic downregulation. Prog Neuropsychopharmacol Biol Psychiatry 12:575–584
Bylund DB, Snyder SH (1976) Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 12:568–580
Charney DS, Menkes DB, Heninger GR (1981) Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry 38:1160–1180
Clements-Jewery S (1978) The development of cortical β-adrenoreceptor subsensitivity in the rat by chronic treatment with trazodone, doxepin and mianserin. Neuropharmacology 17:779–781
Enna SJ, Mann E, Kedall D, Stancel GM (1981) Effect of chronic antidepressant administration on brain neurotransmitter receptor binding. In: Enna SJ, Malick JB, Richelson E (eds) Antidepressants: neurochemical, behavioral, and clinical perspectives. Raven, New York, pp 91–105
Lee T, Tang SW (1984) Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res 12:277–285
Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3H]Ketanserin (R 41 468) a selective 3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:301–314
Maggi A, U’Prichard DC, Enna SJ (1980) Differential effects of antidepressant treatment on brain monoaminergic receptors. Eur J Pharmacol 61:91–98
Matsubara R, Matsubara S, Koyama T, Muraki A, Yamashita I (1993) Effect of chronic treatment with milnacipran (TN-912), a novel antidepressant, on β-adrenergic-receptoradenylate cyclase system and serotonin2 receptor in the rat cerebral cortex. Jpn J Neuropsychopharmacol 15:119–126
Meyerson LR, Ong HH, Martin LL, Ellis DB (1980) Effect of antidepressant agents on β-adrenergic receptor and neurotransmitter regulatory systems. Pharmacol Biochem Behav 12:943–948
Peroutka SJ, Snyder SH (1980) Regulation of serotonin2 (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215:582–587
Reynolds CP, Garrett NJ, Rupniak N, Jenner P, Marsden CD (1983) Chronic clozapine treatment of rats down-regulates 5-HT2 receptors. Eur J Pharmacol 89:325–326
Savage DD, Frazer A, Mendels J (1979) Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on 3H-serotonin receptor binding in rat brain. Eur J Pharmacol 58:87–88
Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 51:660–672
Schmidt CJ, Black CK, Taylor VL, Fadayel GM, Humphreys TM, Nieduzak TR, Sorensen SM (1992) The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 220:151–159
Scott JA, Crews FT (1983) Rapid decrease in rat brain beta-adrenergic receptor binding during combined antidepressant-alpha-2 antagonist treatment. J Pharmacol Exp Ther 224:640–646
Segawa T, Mizuta T, Nomura Y (1979) Modifications of central 5-hydroxytryptamine binding sites in synaptic membranes from rat brain after long-term administration of tricyclic antidepressants. Eur J Pharmacol 58:75–83
Sellinger-Barnette MM, Mendels J, Frazer A (1980) The effect of psychoactive drugs on beta-adrenergic receptor binding in rat brain. Neuropharmacology 19:447–454
Vetulani J, Stawarz RJ, Dingell JV, Sulser F (1976) A possible common mechanism of action of antidepressant treatments: reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn Schmiedebergs Arch Pharmacol 293:109–114
Wilmot CA, Szczepanik AM (1989) Effects of acute and chronic treatment with clozapine and haloperidol on serotonin (5HT2) and dopamine (D2) receptors in the rat brain. Brain Res 487:288–298
Measurement of β-Adrenoreceptor Stimulated Adenylate Cyclase
Banerjee SP, Kung SL, Riggi SJ, Chanda SK (1977) Development of β-adrenergic receptor subsensitivity by antidepressants. Nature 268:455–456
Clements-Jewery S (1978) The development of cortical β-adrenoreceptor subsensitivity in the rat by chronic treatment with trazodone, doxepin and mianserin. Neuropharmacology 17:779–781
Heal D, Cheetham SH, Martin K, Browning J, Luscombe G, Buckett R (1992) Comparative pharmacology of dothiepin, its metabolites, and other antidepressant drugs. Drug Dev Res 27:121–135
Lefkowitz RJ, Stadel JM, Caron MG (1983) Adenylate cyclasecoupled beta-adrenergic receptors. Structure and mechanisms of activation and desensitization. Ann Rev Biochem 52:159–186
Maggi A, U’Prichard DC, Enna SJ (1980) Differential effects of antidepressant treatment on brain monoaminergic receptors. Eur J Pharmacol 61:91–98
Meyerson LR, Ong HH, Martin LL, Ellis DB (1980) Effect of antidepressant agents on β-adrenergic receptor and neurotransmitter regulatory systems. Pharmacol Biochem Behav 12:943–948
Salomon Y (1979) Adenylate cyclase assay. In: Brooker G, Greengard P, Robinson GA (eds) Advances in cyclic nucleotide research, vol 10. Raven, New York, pp 35–55
Sulser F (1978) Functional aspects of the norepinephrine receptor coupled adenylate cyclase system in the limbic forebrain and its modification by drugs which precipitate or alleviate depression: molecular approaches to an understanding of affective disorders. Pharmacopsychiatry 11:43–52
Vetulani J, Stawarz RJ, Dingell JV, Sulser F (1976) A possible common mechanism of action of antidepressant treatments: reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn Schmiedebergs Arch Pharmacol 293:109–114
Wolfe BB, Harden TK, Sporn JR, Molinoff PB (1978) Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther 207:446–457
[3H]Yohimbine Binding to α 2-Adrenoceptors in Rat Cerebral Cortex
Johnson RW, Reisine T, Spotnitz S, Weich N, Ursillo R, Yamamura HI (1980) Effects of desipramine and yohimbine on a α 2- and β-adrenoreceptor sensitivity. Eur J Pharmacol 67:123–127
Scott JA, Crews FT (1983) Rapid decrease in rat brain beta-adrenergic receptor binding during combined antidepressant-alpha-2 antagonist treatment. J Pharmacol Exp Ther 224:640–646
Starke K, Borowski E, Endo T (1975) Preferential blockade of presynaptic α-adrenoceptors by yohimbine. Eur J Pharmacol 34:385–388
Test for Anticholinergic Properties by [3H]-QNB Binding to Muscarinic Cholinergic Receptors in Rat Brain
Hollister LE (1964) Complications from psychotherapeutic drugs. Clin Pharmacol Ther 5:322–333
Marks MJ, Romm E, Collins AC (1987) Genetic influences on tolerance development with chronic oxotremorine infusion. Pharmacol Biochem Behav 27:723–732
Meyerhöffer A (1972) Absolute configuration of 3-quinuclidinyl benzilate and the behavioral effect in the dog of the optical isomers. J Med Chem 15:994–995
Smith CP, Huger FP (1983) Effects of zinc on [3H]-QNB displacement by cholinergic agonists and antagonists. Biochem Pharmacol 32:377–380
Snyder SH, Yamamura HI (1977) Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 34:236–239
Snyder SH, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31:58–61
Wamsley JK, Gehlert DL, Roeske WR, Yamamura HI (1984) Muscarinic antagonist binding site as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine. Life Sci 34:1395–1402
Yamamura HI, Snyder SH (1974) Muscarinic cholinergic binding in rat brain (quinuclidinyl benzilate/receptors). Proc Natl Acad Sci U S A 71:1725–1729
Monoamine Oxidase Inhibition: Inhibition of Type A and Type B Monoamine Oxidase Activities in Rat Brain Synaptosomes
Callingham BA (1989) Biochemical aspects of the pharmacology of moclobemide. The implications of animal studies. Br J Psychiatry 155(Suppl 6):53–60
Cesura AM, Pletscher A (1992) The new generation of monoamine oxydase inhibitors. Prog Drug Res 38:171–297
Colzi A, d’Agostini F, Cesura AM, Da Prada M (1992) Brain microdialysis in rats: a technique to reveal competition between endogenous dopamine and moclobemide, a RIMA antidepressant. Psychopharmacology (Berl) 106:S17–S20
Frankhauser C, Charieras T, Caille D, Rovei V (1994) Interaction of MAO inhibitors and dietary tyramine: a new experimental model in the conscious rat. J Pharmacol Toxicol Methods 32:219–224
Haefeli W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M (1992) Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 106:S6–S14
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297
Kettler R, Da Prada M, Burkard WP (1990) Comparison of monoamine oxydase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiat Scand 82:101–102
Knoll J (1980) Monoamine oxidase inhibitors: chemistry and pharmacology. In: Sandler M (ed) Enzyme inhibitors as drugs. University Park Press, Baltimore, pp 151–173
Ozaki M, Weissbach H, Ozaki A, Witkop B, Udenfriend S (1960) Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro. J Med Pharmacol Chem 2:591–607
Rowler CJ, Ross SB (1984) Selective inhibitors of monoamine oxydase A and B: biochemical, pharmacological, and clinical parameters. Med Res Rev 4:323–358
Waldmeier PC (1993) Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, Brofaromine. Prog Neuro Psychopharmacol Biol Psychiat 17:183–198
Waldmeier PC, Stöcklin K (1990) Binding of [3H]brofaromine to monoamine oxydase A in vivo: displacement by clorgyline and moclobemide. Eur J Pharmacol 180:297–304
White HL, Scates PW (1992) Mechanism of monoamine oxydase inhibition by BW 137U87. Drug Dev Res 25:185–193
Wurtman RJ, Axelrod J (1963) A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol 12:1439–1441
Catalepsy Antagonism
Czermak J (1873) Beobachtungen und Versuche über “hypnotische” Zustände bei Thieren. Pflüger’s Arch ges Physiol 7:107–121
Danilewski B (1881) Über die Hemmungen der Reflex- und Willkürbewegungen. Beiträge zur Lehre vom thierischen Hypnotismus. Pflüger’s Arch ges Physiol 24:489–525
De la Cruz F, Junquera J (1993) The immobility response elicited by clamping, bandaging and grasping in the Mongolian gerbil (Meriones unguiculatus). Behav Brain Res 54:165–169
Gabriel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261–267
Heubel E (1877) Über die Abhängigkeit des wachen Gehirnzustandes von äusseren Erregungen. Ein Beitrag zur Physiologie des Schlafes und zur Würdigung des Kircher’schen Experimentum mirabile. Pflüger’s Arch ges Physiol 14:158–210
Kircher A (1646) Experimentum mirabile. De imaginatione gallinae. In: “Ars magna lucis et umbrae” Romae, Lib. LL, pars I, 154
Schwenter D (1636) Deliciae physico-mathematicae oder Mathematische und Philosophische Erquickstunden. Nürnberg
Simiand J, Guitard J, Griebel G, Soubrié P (2003) Tonic immobility in gerbils. A new model for detecting antidepressant-like effects. Behav Pharmacol 14(Suppl 1):5–40
Verworn M (1898) Beitraege zur Physiologie des Centralnerven-systems. Erster Theil. Die sogenannte Hypnose der Thiere. G Fischer Jena, pp 92
Vogel G, Ther L (1963) Zur Wirkung der optischen Isomeren von Aethyltryptaminacetat auf die Lagekatalepsie des Huhnes und auf die Motilität der Maus. Arzneim Forsch/Drug Res 13:779–783
Despair Swim Test
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: a new potential antidepressant. Drug Dev Res 25:267–282
Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl) 94(147):160
Buckett WR, Fletcher J, Hopcroft RH, Thomas PC (1982) Automated apparatus for behavioural testing of typical and atypical antidepressants in mice. Br J Pharmacol 75:170
Buckley MJ, Surowy C, Meyer M, Curzon P (2004) Mechanism of action of A-85380 in an animal model of depression. Prog Neuropsychopharmacol Biol Psychiatry 28:723–730
Cervo L, Samanin R (1987) Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A agonist. Eur J Pharmacol 144:223–229
Giardina WJ, Ebert DM (1989) Positive effects of captopril in the behavioral despair swim test. Biol Psychiatry 25:697–702
Galea LAM, Wide JK, Barr AM (2001) Estradiol alleviates depressive-like symptoms in a novel animal model of postpartum depression. Behav Brain Res 122:1–9
Gregus A, Wintink AJ, Davis AC, Kalynchuk LE (2005) Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav Brain Res 156:105–114
Hata T, Itoh E, Nishikawa H (1995) Behavioral characteristics of SART-stressed mice in the forced swim test and drug action. Pharmacol Biochem Behav 51:849–853
Kauppila T, Tanila H, Carlson S, Taira T (1991) Effects of atipamezole, a novel α 2-adrenoreceptor antagonist, in open-field, plus-maze, two compartment exploratory, and forced swimming tests in the rat. Eur J Pharmacol 205:177–182
Krahe TE, Filgueiras CC, Schmidt SL (2002) Effects of rotational side preferences in immobile behavior of normal mice in the forced swimming test. Prog Neuropsychopharm Biol Psychiatry 26:169–176
López-Rubalcava C, Lucki I (2000) Strain differences in the behavioral effects of antidepressant drugs in the rat forced swim test. Neuropsychopharmacology 22:191–199
Lucki I (1997) The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8:523–532
Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of psychopharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 155:315–322
Naitoh H, Yamaoka K, Nomura S (1992) Behavioral assessment of antidepressants. 1. The forced swimming test: a review of its theory and practical application. Jpn J Psychopharmacol 12:105–111
Nishimura H, Tsuda A, Ida Y, Tanaka M (1988) The modified forced-swim test in rats: influence of rope- or straw-suspension on climbing behavior. Physiol Behav 43:665–668
Nishimura H, Ida Y, Tsuda A, Tanaka M (1989) Opposite effects of diazepam and β-CCE on immobility and straw-climbing behavior of rats in a modified forced-swim test. Pharmacol Biochem Behav 33:227–231
Nishimura H, Tanaka M, Tsuda A, Gondoh Y (1993) Atypical anxiolytic profile of buspirone and a related drug, SM-3997, in a modified forced swim test employing straw suspension. Pharmacol Biochem Behav 46:647–651
Nomura S, Shimizu J, Kinjo M, Kametani H, Nakazawa T (1982) A new behavioral test for antidepressant drugs. Eur J Pharmacol 83:171–175
Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioural despair in rats: a new model sensitive to antidepressive treatments. Eur J Pharmacol 47:379–391
Porsolt RD, Bertin A, Jalfre M (1977a) Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336
Porsolt RD, Le Pichon M, Jalfre M (1977b) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730–732
Porsolt RD, Martin P, Lenègre A, Fromage S, Drieu K (1990) Effects of an extract of Ginkgo biloba (EGB 761) on “learned helplessness” and other models of stress in rodents. Pharmacol Biochem Behav 36:963–971
Porsolt RD, Lenègre A, McArthur RA (1991) Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser Verlag, Basel, pp 137–159
Sachdev PS, McBride R, Loo C, Mitchell PM, Malhi GS, Crooker V (2002) Effect of different frequencies of transcranial magnetic stimulation (TMS) on the forced swim model of depression in rats. Biol Psychiatry 51:474–479
Stoffel EC, Craft RM (2004) Ovarian hormone withdrawalinduced “depression” in female rats. Physiol Behav 83:505–513
Sun MK, Alkon DL (2003) Open space swimming test to index antidepressant activity. J Neurosci Methods 126:35–40
Sun MK, Alkon DL (2004) Induced depressive behavior impairs learning and memory in rats. Neuroscience 129:129–139
van der Heyden JAM, Olivier B, Zethof TJJ (1991) The behavioral despair model as a prediction of antidepressant activity: effects of serotonergic drugs. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 211–215
Wallach MB, Hedley LR (1979) The effects of antihistamines in a modified behavioral despair test. Commun Psychopharmacol 3:35–39
Weiss JM, Cierpial MA, West CHK (1998) Selective breeding of rats for high and low motor activity in a swim test: toward as new animal model of depression. Pharmacol Biochem Behav 61:49–66
Tail Suspension Test in Mice
Chermat R, Thierry B, Mico JA, Stéru L, Simon P (1986) Adaptation of the tail suspension test to the rat. J Pharmacol 17:348–350
Liu X, Gershenfeld HK (2001) Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biol Psychiatry 49:575–581
Mayorga AJ, Lucki I (2001) Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacology (Berl) 155:110–112
Porsoit RD, Charmat R, Lenègre A, Avril I, Janvier S, Stéru L (1987) Use of the automated tail suspension test for the primary screening of psychotropic agents. Arch Int Pharmacodyn Ther 288:11–30
Porsoit RD, Lenègre A, McArthur RA (1991) Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser Verlag, Basel, pp 137–159
Ripoli N, David DJP, Dailly E, Hascoët M, Bourin M (2003) Antidepressant-like effects in various mice strains in the tail suspension test. Behav Brain Res 143:193–200
Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, Rocha BA (2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 14:573–582
Steru L, Chermat R, Thierry B, Simon P (1985) Tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85:367–370
Stéru L, Chermat R, Thierry B, Mico JA, Lenègre A, Stéru M, Simon P (1987) The automated tail suspension test: a computerized device which differentiates psychotropic drugs. Prog Neuro Psychopharmacol Biol Psychiatry 11:659–671
Trullas R, Jackson B, Skolnick P (1989) Genetic differences in a tail suspension test for evaluating antidepressant activity. Psychopharmacology (Berl) 99:287–288
van der Heyden J, Molewijk E, Olivier B (1987) Strain differences in response to drugs in the tail suspension test for antidepressant activity. Psychopharmacology (Berl) 92:127–130
Vaugeois JM, Odèvre C, Loisel L, Costentin J (1996) A genetic mouse model of helplessness sensitive to imipramine. Eur J Pharmacol 316:R1–R2
Learned Helplessness in Rats
Christensen AV, Geoffroy M (1991) The effect of different serotonergic drugs in the learned helplessness model of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhâuser Verlag, Basel, pp 205–209
Curzon G, Kennett GA, Sarna GS, Whitton PS (1992) The effects of tianeptine and other antidepressants on a rat model of depression. Br J Psychiatry 160(Suppl 15):51–55
Gambarana C, Scheggi S, Tagliamonta A, Tolu P, DeMontis MG (2001) Animals models for the study of antidepressant activity. Brain Res Brain Res Protoc 7:11–20
Ghiglieri O, Gambarana C, Scheggi S, Tagliamonte A, Willner P, De Montis MG (1997) Palatable food induces an appetitive behaviour in satiated rats which can be inhibited by chronic stress. Behav Pharmacol 8:619–628
Giral P, Martin P, Soubrie P, Simon P (1988) Reversal of helpless behavior in rats by putative 5-HT1A agonists. Biol Psychiatry 23:237–242
King JA, Campell D, Edwards E (1993) Differential development of the stress response in congenital learned helplessness. Int J Dev Neurosci 11:435–442
Maier SF, Seligman MEP (1976) Learned helplessness: theory and evidence. J Exp Psychol 105:3–46
Martin P, Soubrié P, Simon P (1986) Noradrenergic and opioid mediation of tricyclic-induced reversal of escape deficits caused by inescapable shock pretreatment in rats. Psychopharmacology 90:90–94
Overmier JB, Seligman MEP (1967) Effects of inescapable shock upon subsequent escape and avoidance learning. J Comp Physiol Psychol 63:28–33
Porsolt RD, Martin P, Lenègre A, Fromage S, Drieu K (1990) Effects of an extract of Ginkgo biloba (EGB 761) on “learned helplessness” and other models of stress in rodents. Pharmacol Biochem Behav 36:963–971
Porsolt RD, Lenègre A, McArthur RA (1991) Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 137–159
Reid I, Forbes N, Stewart C, Matthews K (1997) Chronic stress and depressive disorder: a useful new model. Psychopharmacology (Berl) 134:365–367
Sherman AD, Allers GL, Petty F, Henn FA (1979) A neuropharmacologically-relevant animal model of depression. Neuropharmacology 18:891–893
Shumake J, Poremba A, Edwards E, Gonzalez-Lima F (2000) Congenital helpless rats as a genetic model for cortex metabolism in depression. Neuroreport 11:3793–3798
Simiand J, Keane PE, Guitard J, Langlois X, Gonalons N, Martin P, Bianchetti A, LeFur G, Soubrie P (1992) Antidepressive profile in rodents of SR 5811A, a new selective agonist for atypical β-adrenoreceptors. Eur J Pharmacol 219:193–201
Tejedor del Real P, Gilbert-Rahola J, Leonsegui I, Micó JA (1991) Relationship between emotivity level and susceptibility to the learned helplessness model of depression in the rat. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 217–224
Vaccheri A, Dall’Olio R, Gaggi R, Gandolfi O, Montanaro N (1984) Antidepressant versus neuroleptic activities of sulpiride isomers on four animal models of depression. Psychopharmacology (Berl) 83:28–33
Vollmayr B, Henn FA (2001) Learned helplessness in the rat: improvements in validity and reliability. Brain Res Brain Res Protoc 8:1–7
Vollmayr B, Faust H, Lewicka S, Henn FA (2001) Brainderived-neurotrophic-factor (BDNF) stress responses in rats bred for learned helplessness. Mol Psychiatry 6:471–474
Vollmayr B, Bachteler D, Vangelien V, Gass P, Spanagel R, Henn F (2004) Rats with congenital learned helplessness respond less to sucrose but show no deficits in activity or learning. Behav Brain Res 150:217–221
Weiss JMO, Kilts CD (1998) Animal models of depression and schizophrenia. In: Nemeroff CB, Schatzberg AF (eds) Textbook of psychopharmacology, 2nd edn. American Psychiatric Press, Bethesda, pp 88–123
Muricide Behavior in Rats
Barnett A, Taber RI, Roth FE (1969) Activity of antihistamines in laboratory antidepressant tests. Int J Neuropharmacol 8:73–79
Horovitz ZP, Ragozzino PW, Leaf RC (1965) Selective block of rat mouse-killing by anti-depressants. Life Sci 4:1909–1912
Horovitz ZP, Piala JJ, High JP, Burke JC, Leaf RC (1966) Effects of drugs on the mouse-killing (muricide) test and its relationship to amygdaloid functions. Int J Neuropharmacol 5:405–411
Karli P (1956) The Norway rats’s killing response to the white mouse: an experimental analysis. Behaviour 10:81–103
Karli P, Vergnes M, Didiergeorges F (1969) Rat-mouse interspecific aggressive behaviour and its manipulation by brain ablation and by brain stimulation. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 47–55
Kreiskott H (1969) Some comments on the killing response behaviour of the rat. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 56–58
Kulkarni AS (1968) Muricidal block produced by 5-hydroxytryptophan and various drugs. Life Sci 7:125–128
McCarthy D (1966) Mouse-killing induced in rats treated with pilocarpine. Fed Proc 25:385, Abstract
McMillen BA, Chamberlain JK, DaVanzo JP (1988) Effects of housing and muricidal behavior on serotonergic receptors and interactions with novel anxiolytic drugs. J Neural Transm 71:123–132
Molina V, Ciesielski L, Gobaille S, Isel F, Mandel P (1985) Inhibition of mouse killing behavior by serotonin-mimetic drugs: effects of partial alterations of serotonin neurotransmission. Pharmacol Biochem Behav 27:123–131
Sofia RD (1969a) Effects of centrally active drugs on experimentally-induced aggression in rodents. Life Sci 8:705–716
Sofia RD (1969b) Structural relationship and potency of agents which selectively block mouse-killing (muricide) behavior in rats. Life Sci 8:1201–1210
Vergnes M, Kempf E (1982) Effect of hypothalamic injections of 5,7-dihydroxytryptamine on elicitation of mouse-killing in rats. Behav Brain Res 5:387–397
Vogel JR (1975) Antidepressant and mouse-killing (muricide) behavior. In: Fielding S, Lal H (eds) Industrial pharmacology, vol II, Antidepressants. Futura, Mount Kisco, pp 99–112
Vogel JR, Leaf RC (1972) Initiation of mouse-killing in nonkiller rats by repeated pilocarpine treatment. Physiol Behav 8:421–424
Wnek DJ, Leaf RC (1973) Effects of cholinergic drugs on preykilling in rodents. Physiol Behav 10:1107–1113
Behavioral Changes After Neonatal Clomipramine Treatment
Bonilla-Jaime H, Retana-Marquez S, Velasquez-Moctezuma J (1998) Pharmacological features of masculine sexual behavior in an animal model of depression. Pharmacol Biochem Behav 60:39–45
Drago F, Continella G, Alloro MC, Scapagnini U (1985) Behavioral effects of perinatal administration of antidepressant drugs in the rat. Neurobehav Toxicol Teratol 7:493–497
Dwyer SM, Rosenwasser AM (1998) Neonatal clomipramine treatment, alcohol intake and circadian rhythms in rats. Psychopharmacology (Berl) 138:176–183
Feenstra MGP, van Galen H, Te Riele PJM, Botterblom MHA, Mirmiran M (1996) Decreased hypothalamic serotonin levels in adult rats treated neonatally with clomipramine. Pharmacol Biochem Behav 55:647–652
Frank MG, Heller HC (1997) Neonatal treatments with the serotonin uptake inhibitors clomipramine and zimelidine, but not the noradrenaline uptake inhibitor desipramine, disrupt sleep pattern in rats. Brain Res 768:287–293
Hansen HH, Mikkelsen JD (1998) Long-term effects on serotonin transporter mRNA expression of chronic neonatal exposure to a serotonin reuptake inhibitor. Eur J Pharmacol 253:307–315
Hansen HH, Sanchez C, Meier E (1997) Neonatal administration of the selective serotonin reuptake inhibitor Lu 10–134-C increases forced swimming-induced immobility in adult rats. A putative animal model of depression? J Pharmacol Exp Ther 283:133–1341
Hartley P, Neill D, Hagler M, Kors D, Vogel G (1990) Procedure- and age-dependent hyperactivity in a new animal model of endogenous depression. Neurosci Biobehav Rev 14:69–72
Kinney GG, Vogel GW, Feng P (1997) Decreased dorsal raphe nucleus neuronal activity in adult chloral hydrate anesthetized rats following neonatal clomipramine treatment: implications for endogenous depression. Brain Res 756:68–75
Maudhuit C, Hamon M, Adrien J (1995) Electrophysiological activity of raphe dorsalis serotoninergic neurones in a possible model of endogenous depression. NeuroReport 6:681–684
Maudhuit C, Hamon M, Adrien J (1996) Effects of chronic treatment with zimelidine and REM sleep deprivation on the regulation of raphe neuronal activity in a rat model of depression. Psychopharmacology (Berl) 124:267–274
Mirmiran M, van de Poll NE, Corner MA, van Oyen HG, Bour HL (1981) Suppression of active sleep by chronic treatment with chlorimipramine during early postnatal development: effects upon adult sleep and behavior in rats. Brain Res 204:129–146
Neill D, Vogel G, Hagler M, Kors D, Hennessy A (1990) Diminished sexual activity in a new animal model of endogenous depression. Neurosci Biobehav Rev 14:73–76
Prathiba J, Kumar KB, Karanth KS (1995) Effects of neonatal clomipramine on cholinergic receptor sensitivity and passive avoidance behavior in adult rats. J Neural Transm Gen Sect 100:93–99
Prathiba J, Kumar KB, Karanth KS (1997) Fear-potentiated post-startle activity in neonatal clomipramine treated rats. Indian J Pharmacol 29:201–203
Prathiba J, Kumar KB, Karanth KS (1998) Hyperactivity of hypothalamic pituitary axis in neonatal clomipramine model of depression. J Neural Transm 105:1335–1339
Prathiba J, Kumar KB, Karanth KS (1999) Effects of chronic administration of imipramine on the hyperactivity of hypothalamic-pituitary-adrenal axis in neonatal clomipramine treated rats. Indian J Pharmacol 31:225–228
Rodriguez-Echandia EL, Broitman ST (1983) Effect of prenatal and postnatal exposure to therapeutic doses of chlorimipramine to emotionality in the rat. Psychopharmacology (Berl) 79:236–241
Velazquez-Moctezuma J, Diaz-Ruiz O (1992) Neonatal treatment with clomipramine increased immobility in the forced swim test: an attribute of animal models of depression. Pharmacol Biochem Behav 42:737–739
Velazquez-Moctezuma J, Aguillar-Garcia A, Diaz-Ruiz O (1993) Behavioral effects of neonatal treatment of clomipramine, scopolamine, and idazoxan in male rats. Pharmacol Biochem Behav 46:215–217
Vázquez-Palacios G, Bonilla-Jaime H, Velázquez-Moctezuma J (2005) Antidepressant effects of nicotine and fluoxetine in an animal model of depression induced by neonatal treatment with clomipramine. Prog Neuropsychopharmacol Biol Psychiatry 29:39–46
Vogel G, Hagler M (1996) Effects of neonatally administered iprindole on adult behaviors of rats. Pharmacol Biochem Behav 55:157–161
Vogel G, Hartley P, Neill D, Hagler M, Kors D (1988) Animal depression model by neonatal clomipramine: reduction of shock induced aggression. Pharmacol Biochem Behav 31:103–106
Vogel G, Neill D, Hagler M, Kors D (1990a) A new animal model of endogenous depression: a summary of present findings. Neurosci Biobehav Rev 14:85–91
Vogel G, Neill D, Kors D, Hagler M (1990b) REM sleep abnormalities in a new model of endogenous depression. Neurosci Biobehav Rev 14:77–83
Vogel GW, Buffenstein A, Minter K, Hennessey A (1990c) Drug effects on REM sleep and on endogenous depression. Neurosci Biobehav Rev 14:49–63
Vogel G, Neill D, Hagler M, Kors D, Hartley P (1990d) Decreased intracranial self-stimulation in a new animal model of endogenous depression. Neurosci Biobehav Rev 14:65–68
Vogel G, Hagler M, Hennessey A, Richard C (1996) Dosedependent decrements in adult male sexual behavior after neonatal clomipramine treatment. Pharmacol Biochem Behav 54:605–609
Yavari P, Vogel GW, Neill DB (1993) Decreased raphe unit activity in a rat model of endogenous depression. Brain Res 611:31–36
Chronic Stress Model of Depression
Ducottet C, Griebel G, Belzung C (2003) Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the mild stress model of depression in mice. Prog Neuropsychopharm Biol Psychiatry 27:625–631
Forbes NF, Stewart CA, Metthews K, Reid IC (1996) Chronic mild stress and sucrose consumption: validity as a model of depression. Physiol Behav 60:1481–1484
Gabriel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261–267
Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrié P (2002a) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A 99:6370–6375
Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrié P (2002b) 4-(2-Chloro-4-methoxy-5-methylphenyl)-VV[(15″)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-V-(2-propynyl)1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophinreleasing factor1 receptor antagonist. LL. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:332–345
Grippo AJ, Beltz TG, Johnson AK (2003) Behavioral and cardiovascular changes in the chronic mild stress model of depression. Physiol Behav 78:703–710
Harkin A, Houlihan DD, Kelly JP (2002) Reduction in preference for saccharin by repeated unpredictable stress in mice and its prevention by imipramine. J Psychopharmacol 16:115–123
Konkle ATM, Baker SL, Kentner AC, Barbagallo LSM, Merali Z, Bielajew C (2003) Evaluation of the effects of chronic mild stressors on hedonic and physiological responses: sex and strain compared. Brain Res 992:227–238
Kopp C, Vogel E, Rettori MC, Delagrange P, Misslin R (1999) The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav Pharmacol 10:73–83
Matthews K, Robbins TW (2003) Early experience as a determinant of adult behavioural responses to reward: the effects of repeated maternal separation in the rat. Neurosci Biobehav Rev 27:45–55
Moreau JL, Bös M, Jenck F, Martin JR, Mortas P, Wichmann J (1996) 5-HT2C receptor antagonists exhibit antidepressantlike properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 6:169–175
Muscat R, Kyprianou T, Osman M, Phillips G, Willner P (1991) Sweetness-dependent facilitation of sucrose drinking by raclopride is unrelated to caloric content. Pharmacol Biochem Behav 40:209–213
Papp M, Wieronska J (2000) Antidepressant-like activity of amisulpiride in two animal models of depression. J Psychopharmacol 14:46–52
Pijlman FTA, Wolterink G, van Ree JM (2003) Physical and emotional stress have differential effects on preference for saccharine and open field behavior in rats. Behav Brain Res 139:131–138
Sammut S, Goodall G, Muscat R (2001) Acute interferon-a administration sucrose consumption in the rat. Psychoendocrinology 26:261–272
Sammut S, Bethus I, Goodall G, Muscat R (2002) Antidepressant reversal of interferon-a-induced anhedonia. Physiol Behav 75:765–772
Strekalova T, Spanagel R, Bartsch D, Henn FA, Gass P (2004) Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology 29:2007–2017
Willner P (1997) Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 134:319–329
Willner P, Mitchell PJ (2002) The validity of animal models of predisposition to depression. Behav Pharmacol 13:169–188
Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987) Reduction in sucrose preference by chronic unpredictable mild stress, and its restoration by a cyclic antidepressant. Psychopharmacology (Berl) 93:358–364
Willner P, Muscat R, Papp M (1992) Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16:525–534
Novelty-Induced Hypophagia Test
Blier P (2003) The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13:57–66
Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 163:121–141
Brodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ (1988) Effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 95:298–302
Brodnoff SR, Suranyi-Cadotte B, Quirion R, Meaney MJ (1989) A comparison of the effects of diazepam versus several typical and atypical antidepressant drugs in an animal model of anxiety. Psychopharmacology (Berl) 97:277–279
Cyran JF, Mombereau C (2004) In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9:326–357
Cyran JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and further needs. Trends Pharmacol Sci 23:238–245
Dulawa SC, Hen R (2005) Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Behav Rev 29:771–783
Dulawa SC, Holick KA, Gundersen B, Hen R (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29:1321–1330
Reduction of Submissive Behavior
Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C, Crites G, Malatynska E (2002) Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 440:27–35
Leo GC, Caldwell GW, Crooke J, Malatynska E, Cotto C, Hastings B, Scowcroft J, Hall J, Browne K, Hageman W (2005) The application of nuclear magnetic resonancebased metabonomics to the dominant-submissive rat behavioral model. Anal Biochem 339:174–178
Malatynska E, Kostowski W (1984) The effect of antidepressant drugs on dominance behavior in rats competing for food. Pol J Pharmacol Pharm 36:531–540
Malatynska E, De Leon I, Allen D, Yamamura HI (1995) Effects of amitriptyline on GABA-stimulated 36Cl-uptake in relation to a behavioral model of depression. Brain Res Bull 37:53–59
Malatynska E, Goldenberg R, Shuck L, Haque A, Zamecki P, Crites G, Schindler N, Knapp RJ (2002) Reduction of submissive behavior in rats: a test for antidepressant drug activity. Pharmacology 54:8–17
Malatynska E, Rapp R, Harrawood D, Tunicliff G (2005) Submissive behavior in mice as a test for antidepressant drug activity. Pharmacol Biochem Behav 82:306–313
Pinhasov A, Crooke J, Rosenthal D, Brenneman D, Malatynska E (2005) Reduction of submission behavior for antidepressant activity testing: study using a video-tracking system. Behav Pharmacol 16:657–664
Animal Models of Bipolar Disorder
Antelmanm SM, Caggiula AR, Kiss S, Edwards DJ, Kocan D, Stiller R (1995) Neurochemical and physiological effects of cocaine oscillate with sequential drug treatment: possibly a major factor in drug variability. Neuropsychopharmacology 12:297–306
Antelman SM, Caggiula AR, Kucinski BJ, Fowler H, Gershon S, Edwards DJ, Austin MC, Stiller R, Kiss S, Kocan D (1998) The effects of lithium on a potential cycling model of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 22:495–510
Arban R, Maraia G, Brackenborough K, Winyard L, Wilson A, Gerrard P, Large C (2005) Evaluation of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res 158:123–132
Caggiula AR, Donny EC, Epstein LH, Sved AF, Knopf S, Rose C, McAllister CG, Antelman SM, Perkins KA (1998a) The role of corticosteroids in nicotine’s physiological and behavioral effects. Psychoneuroendocrinology 23:143–159
Caggiula AR, Antelman S, Kucinski BJ, Fowler H, Edwards DJ, Austin MC, Gershon S, Stiller R (1998b) Oscillatory-sensitization model of repeated drug exposure: cocaine’s effect on shock-induced hypoanalgesia. Prog Neuropsychopharmacol Biol Psychiatry 22:511–521
Cao BJ, Peng NA (1993) Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents. Eur J Pharmacol 237:177–181
D’Aquila PS, Panin F, Serra G (2004) Long-term imipramine withdrawal induces a depressive-like behavior in the forced swimming test. Eur J Pharmacol 492:61–63
Decker S, Grider G, Cobb M, Li XP, Huff MO, El Mallakk RS, Levy RS (2000) Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model for bipolar illness. Prog Neuropsychopharmacol Biol Psychiatry 24:455–462
El Mallakh RS, Harrison LT, Changaris DG, Levy RS (1995) An animal model of mania: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 19:955–962
El Mallakh RS, El Masri MA, Huff MO, Li XP, Decker S, Levy RS (2003) Intracerebroventricular administration of ouabain as a model of mania in rats. Bipolar Disord 5:362–365
Gambarana C, Mangiavacchi S, Masi F, Scheggi S, Tagliamonte A, Tolu P, De Montis MG (2000) Long-term lithium administration abolishes the resistance to stress in rats sensitized to morphine. Brain Res 877:218–225
Gessa GL, Pani L, Fadda P, Fratta W (1995) Sleep deprivation in the rat: an animal model of mania. Eur Neuropsychopharmacol 5:879–893
Gould TJ, Keith RA, Bhat RV (2001) Differential sensitivity to lithium’s reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav Brain Res 118:95–105
Kucinski BJ, Antelman SM, Caggiula AR, Fowler H, Gershon S, Edwards DJ (1999) Cocaine-induced oscillation is conditionable. Pharmacol Biochem Behav 63:449–455
Machado-Vieira R, Kapczinski F, Soares JC (2004) Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 28:209–224
Petty F, Sherman AD (1981) A pharmacologically pertinent animal model of mania. J Affect Disord 3:381–387
Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH (2002) Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm 109:433–440
Wei Q, Lu XY, Liu L, Schafer G, Shieh KR, Burke S, Robinson TE, Watson SJ, Seasholtz AF, Akil H (2004) Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc Natl Acad Sci U S A 101:11851–11856
Animal Models of Obsessive-Compulsive Disorder
Agrati D, Fernández-Guasti A, Zuluaga MJ, Uriarte N, Pereira M, Ferreira A (2005) Compulsive-like behavior according to the sex and the reproductive stage of female rats. Behav Brain Res 161:313–319
Berridge KC, Aldridge JW, Houchard KR, Zhuang X (2005) Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive convulsive disorder and Tourette’s. BMC Biol 3:1–16
Fernández-Guasti A, Ulloa RE, Nicolini H (2003) Age differences in the sensitivity to clomipramine in an animal model of obsessive compulsive disorder. Psychopharmacology (Berl) 166:193–201
Joel D (2006) The signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology (Berl) 186:487–503
Joel D, Avisar A (2001) Excessive lever pressing following post-training signal attenuation in rats: a possible animal model of obsessive compulsive disorder? Behav Brain Res 123:77–87
Joel D, Doljansky J, Roz N, Rehavi N (2005) Role of the orbital cortex and of the serotoninergic system in a rat model of obsessive compulsive disorder. Neuroscience 130:25–36
Nurnberg HG, Keith SJ, Paxton DM (1997) Consideration of the relevance of ethological animal models for human repetitive behavioral spectrum disorders. Biol Psychiatry 41:226–229
Overall KL (2000) Natural animal models of human psychiatric conditions: assessment of mechanism and validity. Prog Neuropsychopharmacol Biol Psychiatry 24:727–776
Stein DJ (2000) Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 47:296–304
Stein DJ (2002) Obsessive-compulsive disorder. Lancet 360:397–405
Stein DJ, Mendelson I, Potocnik F, Von Kradenberg J, Wessels C (1998) Use of the selective serotonin reuptake inhibitor citalopram in a possible animal analogue of obsessive-compulsive disorder. Depress Anxiety 8:39–42
Szechtman H, Eckert MJ, Tse WS, Boersma JT, Bonura CA, McClelland JZ, Culver KE, Eilam D (2001) Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. BMC Neurosci 2:4
Tsaltas E, Kontis DK, Chrysikakou S, Giannou H, Biba A, Pallidi S, Christodoulou A, Maillis A, Rabavilas A (2005) Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology. Biol Psychiatry 57:1176–1185
Ulloa RE, Nicolini H, Fernández-Guasti A (2004a) Sex differences on spontaneous alteration in prepubertal rats: implications for an animal model of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 28:687–692
Ulloa RE, Nicolini H, Fernández-Guasti A (2004b) Age differences in an animal model of obsessive-compulsive disorder: participation of dopamine. Dopamine in an animal model of OCD. Pharmacol Biochem Behav 78:661–666
Van Kuyck K, Demeulmeester H, Feys H, de Weerdt W, Dewil M, Tousseyn T, de Sutter P, Gybels J, Bogaerts K, Dom R, Nuttin B (2003) Effects of electrical stimulation or lesion in nucleus accumbens on the behaviour of rats after administration of 8-OH-DPAT or vehicle. Behav Brain Res 140:165–173
Woods-Kettelberger A, Kongsamut S, Smith CP, Winslow JT, Corbett R (1997) Animal models with potential applications for screening of compounds for the treatment of obsessive-compulsive disorder. Expert Opin Investig Drugs 6:1369–1381
Yadin E, Freidman E, Bridger WH (1991) Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder? Pharmacol Biochem Behav 40:311–315
Antidepressant-Like Activity in Differential-Reinforcement of Low Rate 72-Second Schedule
Andrews JS, Jansen JHM, Linders S, Princen A, Drinkenburg WHIM, Coenders CJH, Vossen JHM (1994) Effects of imipramine and mirtazipine on operant performance in rats. Drug Dev Res 32:58–66
Marek GJ, Seiden LS (1988) Effects of selective 5-hydroxytryptamine-2 and nonselective 5-hydroxytryptamine antagonists on the differential-reinforcement-of -low-rate 72second schedule. J Pharmacol Exp Ther 244:650–658
Marek GJ, Li AA, Seiden LS (1989) Selective 5-hydroxytryptamine2 antagonists have antidepressant-like effects on differential-reinforcement-of -low-rate 72 second schedule. J Pharmacol Exp Ther 250:52–59
McGuire PS, Seiden LS (1980) The effects of tricyclic antidepressants on performance under a differentialreinforcement-of -low-rates schedule in rats. J Pharmacol Exp Ther 214:635–641
O’Donnell JM, Seiden LS (1983) Differential-reinforcement-oflow-rate 72-second schedule: selective effects of antidepressant drugs. J Pharmacol Exp Ther 224:80–88
Pollard GT, Howard JL (1986) Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time >72-s schedule. Psychopharmacology (Berl) 89:253–258
van Hest A, van Drimmelen M, Olivier B (1992) Flesinoxan shows antidepressant activity in a DRL 72-s screen. Psychopharmacology (Berl) 107:474–479
Potentiation of Norepinephrine Toxicity
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: a new potential antidepressant. Drug Dev Res 25:267–282
Sigg EB (1959) Pharmacological studies with Tofranil. Can Psychiatr Assoc J 4:S75–S85
Compulsive Gnawing in Mice
De Feo G, Lisciani R, Pavan L, Samarelli M, Valeri P (1983) Possible dopaminergic involvement in biting compulsion induced by large doses of clonidine. Pharmacol Res Commun 15:613–619
Klawans HL, Rubovits R (1972) An experimental model of tardive dyskinesia. J Neural Transm 33:235–246
Molander L, Randrup A (1974) Investigation of the mechanism by which L-DOPA induces gnawing in mice. Acta Pharmacol Toxicol 34:312–324
Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C (1991) Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196:257–266
Pedersen V, Christensen AV (1972) Antagonism of methylphenidate-induced stereotyped gnawing in mice. Acta Pharmacol Toxicol 31:488–496
Randall PK (1985) Quantification of dopaminergic supersensitization using apomorphine-induced behavior in the mouse. Life Sci 37:1419–1423
Ther L, Schramm H (1962) Apomorphin-Synergismus (Zwangsnagen bei Mäusen) als Test zur Differenzierung psychotroper Substanzen. Arch Int Pharmacodyn Ther 138:302–310
Apomorphine-Induced Hypothermia in Mice
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: a new potential antidepressant. Drug Dev Res 25:267–282
Cox B, Lee TF (1981) 5-Hydroxytryptamine-induced hypothermia in rats as an in vivo model for the quantitative study of 5-hydroxytryptamine receptors. J Pharmacol Methods 5:43–51
Porsolt RD, Lenègre A, McArthur RA (1991) Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser Verlag, Basel, pp 137–159
Puech AJ, Chermat R, Poncelet M, Doaré L, Simon P (1981) Antagonism of hypothermia and behavioural responses to apomorphine: a simple, rapid and discriminating test for screening anti-depressants and neuroleptics. Psychopharmacology (Berl) 75:84–91
Tetrabenazine Antagonism in Mice
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: a new potential antidepressant. Drug Dev Res 25:267–282
Benesová O, Nähunek K (1971) Correlation between the experimental data from animal studies and therapeutic effects of antidepressant drugs. Psychopharmacology (Berl) 20:337–347
Doble A, Girdlestone D, Piot O, Allam D, Betschart J, Boireau A, Dupuy A, Guérémy C, Ménager J, Zundel JL, Blanchard JC (1992) Pharmacological characterisation of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist. Br J Pharmacol 15:27–36
Gylys JA, Muccia PMR, Taylor MK (1963) Pharmacological and toxicological properties of 2-methyl-3-piperidinopyrazine, a new antidepressant. Ann N Y Acad Sci 107:899–913
Jamieson DD, Duffield PH, Cheng D, Duffield AM (1989) Comparison of the central nervous system activity of the aqueous und lipid extract of kava (Piper methysticum). Arch Int Pharmacodyn Ther 301:66–80
Nakagawa T, Ukai K, Kubo S (1993) Antidepressive effects of the stereoisomer cis-dosulepin hydrochloride. Arzneim Forsch/Drug Res 43:11–15
Rubin B, Malone MH, Waugh MH, Burke JC (1957) Bioassay of Rauwolfia roots and alkaloids. J Pharmacol Exp Ther 120:125–136
Reserpine-Induced Hypothermia
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: a new potential antidepressant. Drug Dev Res 25:267–282
Askew BM (1963) A simple screening procedure for imipramine-like antidepressant drugs. Life Sci 10:725–730
Bill DJ, Hughes IE, Stephens RJ (1989) The effects of acute and chronic desimipramine on the thermogenic and hypoactivity responses to α 2-agonists in reserpinized and normal mice. Br J Pharmacol 96:144–152
Bourin M (1990) Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests? Fundam Clin Pharmacol 4:49–64
Bourin M, Poncelet M, Chermat R, Simon P (1983) The value of the reserpine test in psychopharmacology. Arzneim Forsch/Drug Res 33:1173–1176
Colpaert FC, Lenaerts FM, Niemegeers CJE, Janssen PAJ (1975) A critical study of Ro-4–1284 antagonism in mice. Arch Int Pharmacodyn Ther 215:189–239
Koe BK, Lebel LA, Nielsen JA, Russo LL, Saccomano NA, Vinick FJ, Williams IA (1990) Effects of novel catechol ether imidazolidinones on calcium-dependent phosphodiesterase activity, (3H)Rolipram binding, and reserpine-induced hypothermia in mice. Drug Dev Res 21:135–142
Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991) Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant Venlafaxine. Drug Dev Res 23:191–199
Niemegeers CJE (1975) Antagonism of reserpine-like activity. In: Fielding S, Lal H (eds) Industrial pharmacology, vol II, Antidepressants. Futura, Mount Kisco, pp 73–98
Pawlowski L, Nowak G (1987) Biochemical and pharmacological tests for the prediction of ability of monoamine uptake blockers to inhibit the uptake of noradrenaline in vivo: the effects of desimipramine, maprotiline, femoxitine and citalopram. J Pharm Pharmacol 39:1003–1009
Porsolt RD, Lenègre A, McArthur RA (1991) Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser Verlag, Basel, pp 137–159
5-Hydroxytryptophan Potentiation in Mice
Ahtee L, Saarnivaara L (1971) The effect of drugs upon the uptake of 5-hydroxytryptamine and metaraminol by human platelets. J Pharm Pharmacol 23:495–501
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: a new potential antidepressant. Drug Dev Res 25:267–282
Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ (1988) Pharmacological profile of ritanserin: a very specific central serotonin antagonist. Drug Dev Res 15:61–73
Chen G (1964) Antidepressives, analeptics and appetite suppressants. In: Laurence DR, Bacharach AL (eds) Evaluation of drug activities: pharmacometrics. Academic, London/New York, pp 239–260
Corne SJ, Pickering RW, Warner BT (1963) A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol 20:106–120
Martin P, Frances H, Simon P (1985) Dissociation of head twitches and tremors during the study of interactions with 5-hydroxytryptophan in mice. J Pharmacol Meth Ther 13:193–200
Meert TF, Niemegeers JE, Awouters F, Janssen PAJ (2003) Partial and complete blockade of 5-hydroxytryptophan (5-HTP)-induced head twitches in the rat: a study of ritanserin (R55667), risperidone (R64766), and related compounds. Drug Dev Res 13:237–244
Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 262:545–551
Moser PC, Redfern PH (1988) The effect of benzodiazepines on the 5-HT agonist-induced head-twitch response in mice. Eur J Pharmacol 151:223–231
Ortmann R, Martin S, Radeke E, Delini Stula A (1981) Interaction of beta-adrenoreceptor agonists with the serotonergic system in rat brain. A behavioural study using the L-5HTP syndrome. Naunyn Schmiedebergs Arch Pharmacol 316:225–230
Shank RP, Gardocki JF, Schneider CR, Vaught JL, Setler PE, Maryanoff BE, McComsey DF (1987) Preclinical evaluation of McN-5707 as a potential antidepressant. J Pharmacol Exp Ther 242:74–84
Shank RP, Vaught JL, Pelley KA, Setler PE, McComsey DF, Maryanoff BE (1988) McN-5652: a highly potent inhibitor of serotonin uptake. J Pharmacol Exp Ther 247:1032–1038
5-Hydroxytryptophan Potentiation in Rats
Ahtee L, Saarnivaara L (1971) The effect of drugs upon the uptake of 5-hydroxytryptamine and metaraminol by human platelets. J Pharm Pharmacol 23:495–501
Colpaert FC, Janssen PA (1983) The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology 22:993–1000
Hallberg H, Carlson L, Elg R (1985) Objective quantification of tremor in conscious unrestrained rats, exemplified with 5-hydroxytryptamine-mediated tremor. J Pharmacol Methods 13:261–266
Matthews WD, Smith CD (1980) Pharmacological profile of a model for central serotonin receptor activation. Life Sci 26:1397–1403
Shank RP, Gardocki JF, Schneider CR, Vaught JL, Setler PE, Maryanoff BE, McComsey DF (1987) Preclinical evaluation of McN-5707 as a potential antidepressant. J Pharmacol Exp Ther 242:74–84
Yohimbine Toxicity Enhancement
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: a new potential antidepressant. Drug Dev Res 25:267–282
Bourin M, Malinge M, Colombel MC, Larousse C (1988) Influence of alpha stimulants and beta blockers on yohimbine toxicity. Prog Neuropsychopharmacol Biol Psychiatry 12:569–574
Goldberg MR, Robertson D (1983) Yohimbine: a pharmacological probe for study the α 2-adrenoreceptor. Pharmacol Rev 35:143–180
Malick JP (1981) Yohimbine potentiation as a predictor of antidepressant action. In: Enna SJ, Malick JB, Richelson E (eds) Antidepressants: neurochemical, behavioral and clinical perspectives. Raven, New York, pp 141–156
Porsolt RD, Lenègre A, McArthur RA (1991) Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser Verlag, Basel, pp 137–159
Quinton RM (1963) The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice. Br J Pharmacol 21:51–66
Tryptamine Seizure Potentiation in Rats
Graham-Smith DG (1971) Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by Ltryptophan or 5-methoxy-N, N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol 43:856–864
Knoll J (1980) Monoamine oxidase inhibitors: chemistry and pharmacology. In: Sandler M (ed) Enzyme inhibitors as drugs. University Park Press, Baltimore, pp 151–173
Ozaki M, Weissbach H, Ozaki A, Witkop B, Udenfriend S (1960) Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro. J Med Pharmacol Chem 2:591–607
Serotonin Syndrome in Rats
Andersson G, Larsson K (1994) Effects of FG 5893, a new compound with 5-HT1A receptor agonistic and 5-HT2 receptor antagonistic properties, on male rat sexual behavior. Eur J Pharmacol 255:131–137
Arnt J, Hyttel J (1989) Facilitation of 8-OH-DPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol 161:45–51
Bagdy G, To CT (1997) Comparison of relative potencies of i.v. and i.c.v. administered 8-OH-DPAT gives evidence of different sites of action for hypothermia, lower lip retraction and tail flicks. Eur J Pharmacol 323:53–58
Berendsen HG, Broekkamp CLE (1990) Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol 101:667–673
Berendsen HG, Broekkamp CLE (1997) Indirect in vivo 5-HT1A-agonistic effects of the new antidepressant mirtazapine. Psychopharmacology (Berl) 133:275–282
Berendsen HHG, Jenk F, Broekkamp CLE (1989) Selective activation of 5-HT1A receptors induces lower lip retraction in the rat. Pharmacol Biochem Behav 33:821–827
Berendsen HHG, Bourgondien FGM, Broekkamp CLE (1994) Role of dorsal and median raphe nuclei in lower lip retraction in rats. Eur J Pharmacol 263:315–318
Berendsen HHG, Kester RCH, Peeters BWMM, Broekkamp CLE (1996) Modulation of 5-HT receptor subtypemediated behaviours by corticosterone. Eur J Pharmacol 308:103–111
Blanchard RJ, Shepherd JK, Armstrong J, Tsuda SF, Blanchard DC (1993) An ethopharmacological analysis of the behavioral effects of 8-OH-DPAT. Psychopharmacology (Berl) 112:55–65
Blanchard RJ, Griebel G, Guardiola-Lemaître B, Brush MM, Lee J, Blanchard DC (1997) An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome. Pharmacol Biochem Behav 57:897–908
Deakin JFW, Green AR (1978) The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-Dopa in rats. Br J Pharmacol 64:201–209
De Boer T, Ruigt GSF, Berendsen HHG (1995) The alpha-2-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron registered) enhances noradrenergic and serotonergic transmissions. Hum Psychopharmacol 10(Suppl 2):S107–S118
Evenden JL (1994) The effect of 5-HT1A receptor agonists on locomotor activity in the guinea pig. Br J Pharmacol 112:861–866
Foreman MM, Fuller RW, Leander JD, Benvenga MJ, Wong DT, Nelson DL, Calligaro DO, Swanson SP, Lucot JP, Flaugh ME (1993) Preclinical studies in LY228729: a potent and selective serotonin1A agonist. J Pharmacol Exp Ther 267:58–71
Foreman MM, Fuller RW, Rasmussen K, Nelson DL, Calligaro DO, Zhang L, Barrett JE, Booher RN, Paget CJ Jr, Flaugh ME (1994) Pharmacological characterization of LY293284: a 5-HT1A receptor agonist with high potency and selectivity. J Pharmacol Exp Ther 270:1270–1291
Foreman MM, Fuller RW, Leander JD, Nelson DL, Calligaro DO, Lucaites VL, Wong DT, Zhang L, Barrett JE, Schaus HM (1995) Pharmacological characterization of enantiomers of 8-thiomethyl-2-(di-n-propylamino)tetralin, potent and selective 5-HT1A receptor agonists. Drug Dev Res 34:66–85
Forster EA, Cliffed IA, Bill DJ, Dover GM, Jones D, Reilly Y, Fletcher A (1995) A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281:81–88
Gaggi R, DaU’Olio R, Roncada P (1997) Effects of the selective 5-HT receptor agonists 8-OHDPAT and DOI on behavior and brain biogenic amines of rats. Gen Pharmacol 28:583–587
Goodwin GM, Green AR (1985) A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol 84:743–753
Goodwin GM, De Souza RJ, Wood AJ, Green AR (1986) The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a postsynaptic mechanism. Psychopharmacology (Berl) 90:488–493
Green AR, Heal DJ (1985) The effects of drugs on serotoninmediated behavioural models. In: Green A (ed) Neuropharmacol of serotonin. Oxford University Press, Oxford, pp 326–365
Green AR, O’Shaughnessy K, Hammond M, Schächter M, Grahame-Smith DG (1983) Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology 22:573–578
Groenink L, Van der Gugten J, Compaan JC, Maes RAA, Olivier B (1997) Flesinoxan pretreatment differently affects corticosterone, prolactin and behavioural responses to a flesinoxan challenge. Psychopharmacology (Berl) 131:93–100
Jacobs BL (1976) An animal behavior model for studying serotonergic synapses. Life Sci 19:777–786
Kleven MS, Assié MB, Koek W (1997) Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT1A/2C antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. J Pharmacol Exp Ther 282:747–759
Kofman O, Levin U (1995) Myo-inositol attenuates the enhancement of the serotonin syndrome by lithium. Psychopharmacology (Berl) 118:213–218
Lu JQ, Nagayama H (1996) Circadian rhythm in the response of central 5-HT1A receptors to 8-OH-DPAT in rats. Psychopharmacology (Berl) 123:42–45
Martin KF, Phillips I, Hearson M, Prow MR, Heal DJ (1992) Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Br J Pharmacol 107:15–21
Moore NA, Rees G, Sanger G, Perrett L (1993) 5-HT1Amediated lower lip retraction: effects of 5-HT1A agonists and antagonists. Pharmacol Biochem Behav 46:141–143
O’Connell MT, Curzon G (1996) A comparison of the effects of 8-OH-DPAT pretreatment on different behavioural responses to 8-OH-DPAT. Eur J Pharmacol 312:137–143
O’Neill MF, Parameswaran T (1997) RU24699-induced behavioural syndrome requires activation of both 5-HT1A and 5-HT1B receptors. Psychopharmacology (Berl) 132:255–260
Porsolt RD, Lenègre A, Caignard DH, Pfeiffer B, Mocaër E, Guardiola-Lemaître B (1992) Psychopharmacological profile of a new chroman derivative with 5-hydroxytryptamine1A agonist properties: S20499(+). Drug Dev Res 27:389–402
Schoeffter P, Fozard JR, Stoll A, Siegl H, Seiler MP, Hoyer D (1993) SDZ 216–525, a selective and potent 5-HT1A receptor antagonist. Eur J Pharmacol 244:251–257
Simiand J, Keane PE, Barnouin MC, Keane M, Soubrié P, Le Fur G (1993) Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist. Fundam Clin Pharmacol 7:413–427
Smith LM, Peroutka SJ (1986) Differential effects of 5-hydroxytrytamine1A selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav 24:1513–1519
Tricklebank MD (1985) The behavioural response to 5-HT receptor agonists and subtypes of the central 5-HT receptor. Trends Pharmacol Sci 14:403–407
Trulson ME, Eubanks EE, Jacobs BL (1976) Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine. J Pharmacol Exp Ther 198:23–32
Wolff MC, Benvenga MJ, Calligaro DO, Fuller RW, Gidda JS, Hemrick-Luecke S, Lucot JB, Nelson DL, Overshiner CD, Leander JD (1997) Pharmacological profile of LY301317, a potent and selective 5-HT1A agonist. Drug Dev Res 40:17–34
Yu H, Lewander T (1997) Pharmacokinetic and pharmacodynamic studies of (R)-8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur Neuropsychopharmacol 7:165–172
Hypermotility in Olfactory-Bulbectomized Rats
Bilkei-Gorzo A, Racz I, Michel K, Zimmer A (2002) Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci 22:10046–10052
Bissette G (2001) Effects of sertraline on regional neuropeptide concentrations in olfactory bulbectomized rats. Pharmacol Biochem Behav 69:269–281
Briley M, Prost JF, Moret C (1996) Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 11(Suppl 4):9–14
Cairncross KD, Wren A, Cox B, Schieden H (1977) Effects of olfactory bulbectomy and domicile on stress-induced corticosterone release in the rat. Physiol Behav 19:405–487
Cairncross KD, Cox B, Forster C, Wren AF (1978) A new model for the detection of antidepressant drugs: olfactory bulbectomy in the rat compared with existing models. J Pharmacol Methods 1:131–143
Cairncross KD, Cox B, Forster C, Wren AF (1979) Olfactory projection system, drugs and behaviour: a review. Psychoneuroendocrinology 4:253–272
Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, Vinken P, Ashton D, Langlois X, Steckler T (2004) Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278955/CRA0450. Eur J Pharmacol 485:145–158
Cryan JF, McGrath C, Leonard BE, Norman TR (1999) Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. Pharmacol Biochem Behav 63:333–338
Hancock AA, Buckner SA, Oheim KW, Morse PA, Brune ME, Meyer MD, Williams M, Kervin LF Jr (1995) A-80426, a potent α 2-adrenoceptor antagonist with serotonin uptake blocking activity and putative antidepressant-like effects: I. Biochemical profile. Drug Dev Res 35:237–245
Ho YJ, Chang YC, Liu TM, Tai MY, Wong CS, Tsai YF (2000) Striatal glutamate release during novelty exposureinduced hyperactivity in olfactory bulbectomized rats. Neurosci Lett 287:117–120
Holmes PV, Davis RC, Masini CV, Primeaux SD (1998) Effects of olfactory bulbectomy on neuropeptide gene expression in the rat olfactory/limbic system. Neuroscience 86:587–596
Janscár SM, Leonard BE (1984) The effect of (±)mianserin and its enantiomers on the behavioural hyperactivity of the olfactory bulbectomized rat. Neuropharmacology 23:1065–1070
Kelly JP, Leonard BE (1994) The effects of tianeptine and sertraline in three animal models of depression. Neuropharmacology 33:1011–1016
Kelly JP, Leonard BE (1995) The contribution of pre-clinical drug evaluation in predicting the clinical profile of the selective serotonin reuptake inhibitor paroxetine. J Serotonin Res 1:27–46
Kelly JP, Leonard BE (1999) An investigation of the antidepressant properties of lofepramine and its desmethylated metabolites in the forced swim and olfactory bulbectomized rat model of depression. Eur Neuropsychopharmacol 9:101–105
Kelly JP, Wrynn AS, Leonard BE (1997) The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74:299–316
Leonard BE, O’Connor WJ (1984) Effect of isomers of the 6-aza derivative of mianserin on behaviour and noradrenaline metabolism in bulbectomized rats. Br J Pharmacol 82:246P
Leonard BE, Tuite M (1981) Anatomical, physiological and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol 22:251–286
Martin JR, Bös M, Jenck F, Moreau JL, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HHG, Broekkamp CLE, Ruigt GSF, Köhler C, van Delft AML (1998) 5-HT2C receptor antagonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913–924
McGrath C, Norman TR (1999) (+)-S-20499 – a potential antidepressant? A behavioural and neurochemical investigation in the olfactory bulbectomized rat. Eur Neuropsychopharmacol 9:21–27
McNamara MG, Kelly JP, Leonard BE (1995) Effect of 8-OHDPAT in the olfactory bulbectomized rat model of depression. J Serotonin Res 2:91–99
Nowak G, Szewczyk B, Wieronska JM, Branski P, Palucha A, Pilc A, Sadlik K, Piekoszewski W (2003) Antidepressantlike effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull 61:159–164
O’Connor WT, Leonard BE (1986) Effect of chronic administration of the 6-aza analogue of mianserin (ORG 3770) and its enantiomers on behaviour and changes in noradrenaline metabolism of olfactory-bulbectomized rats in the “open field” apparatus. Neuropharmacology 25:267–270
Porsoit RD, Lenègre A, McArthur RA (1991) Pharmacological models of depression. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser Verlag, Basel, pp 137–159
Redmont AM, Kelly JP, Leonard BE (1995) Effect of chronic antidepressant administration on the conditioned taste aversion to 8-OHDPAT in the olfactory bulbectomized rat model of depression. Med Sci Res 23:487–488
Redmont AM, Kelly JP, Leonard BE (1997) Behavioral and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 58:355–359
Slotkin TA, Miller DB, Fumagalli F, McCook EC, Zhang J, Bissette G, Seidler FJ (1999) Modeling geriatric depression in animals: biochemical and behavioral effects of olfactory bulbectomy in young versus old rats. J Pharmacol Exp Ther 289:334–345
Song C, Leonard BE (1994) Serotonin reuptake inhibitors reverse the impairments in behaviour neurotransmitter and immune functions in the olfactory bulbectomized rat. Hum Psychopharmacol 9:135–146
Song C, Early B, Leonard BE (1996a) The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression. Brain Behav Immun 10:1–16
Song C, Early B, Leonard BE (1996b) Behavioural and immunological effects of the antihistamine terfenadine in olfactory bulbectomized rats. Eur Neuropsychopharmacol 6:157–162
Van Riezen H, Leonard BE (1990) Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther 47:21–34
Wren A, van Riezen H, Rigter H (1977) A new animal model for the prediction of antidepressant activity. Pharmakopsychiatr Neuropsychopharmakol 10:96–100
Wrynn AS, MacSweeney CP, Franconi F, Lemaire L, Pouliquen D, Herlidou S, Leonard BA, Ganton J, de Certaines JD (2000) An in-vivo magnetic resonance imaging study on the olfactory bulbectomized rat model of depression. Brain Res 879:193–199
Zhou D, Greksch G, Becker A, Frank C, Pilz J, Hueter G (1998) Serotoninergic hyperinnervation of the frontal cortex in an animal model of depression, the bulbectomized rat. J Neurosci Res 54:109–116
Zueger M, Urani A, Chourbaji S, Zacher C, Roche M, Hrkin A, Gass P (2005) Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neurosci Lett 374:142–146
Sexual Behavior in Male Rats
Ahlenius S, Larsson K (1997) Specific involvement of central 5-HT1A receptors in the mediation of male rat ejaculatory behavior. Neurochem Res 22:1065–1070
Ahlenius S, Larsson K, Svensson L, Hjorth S, Carlsson A, Lindberg P, Wikström H, Sanchez D, Arvidsson LE, Hacksell U, Nilsson JLG (1981) Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. Pharmacol Biochem Behav 15:785–792
Andersson G, Larsson K (1994) Effects of FG 5893, a new compound with 5-HT1A receptor agonistic and 5-HT2 receptor antagonistic properties, on male rat sexual behavior. Eur J Pharmacol 255:131–137
Arnone M, Baroni M, Gai J, Guzzi U, Desclaux MF, Keane PE, Le Fur G, Soubrié P (1995) Effect of ST 59026A, a new 5-HT1A receptor agonist, on sexual activity in male rats. Behav Pharmacol 6:276–282
Barr AM, Florino DF, Phillips AG (1999) Effects of withdrawal from an escalating dose schedule of d-amphetamine on sexual behavior in the male rat. Pharmacol Biochem Behav 64:597–604
Fernández-Guasti A, Rodriguez-Manzo G (1997) OH-DPAT and male rat sexual behavior: partial blockade by noradrenergic lesion and sexual exhaustion. Pharmacol Biochem Behav 56:111–116
Fernández-Guasti A, Escalante A, Agmo Ǻ (1989) Inhibitory actions of various HT1B receptor agonists on rat masculine sexual behaviour. Pharmacol Biochem Behav 34:811–816
Foreman MM, Fuller RW, Leander JD, Benvenga MJ, Wong DT, Nelson DL, Calligaro DO, Swanson SP, Lucot JP, Flaugh ME (1993) Preclinical studies in LY228729: a potent and selective serotonin1A agonist. J Pharmacol Exp Ther 267:58–71
Foreman MM, Fuller RW, Rasmussen K, Nelson DL, Calligaro DO, Zhang L, Barrett JE, Booher RN, Paget CJ Jr, Flaugh ME (1994) Pharmacological characterization of LY293284: a 5-HT1A receptor agonist with high potency and selectivity. J Pharmacol Exp Ther 270:1270–1291
Foreman MM, Fuller RW, Leander JD, Nelson DL, Calligaro DO, Lucaites VL, Wong DT, Zhang L, Barrett JE, Schaus HM (1995) Pharmacological characterization of enantiomers of 8-thiomethyl-2-(di-n-propylamino)tetralin, potent and selective 5-HT1A receptor agonists. Drug Dev Res 34:66–85
Gorzalka BB, Mendelson SD, Watson NV (1990) Serotonin receptor subtypes and sexual behavior. Ann N Y Acad Sci 600:435–446
Mendelson SD, Gorzalka BB (1981) Serotonin antagonist pirenperone inhibits sexual behavior in the male rat: attenuation by quipazine. Pharmacol Biochem Behav 22:565–571
Pomerantz SM, Hepner BC, Wertz JM (1993) 5-HT1A and 5-HT1C/1D receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys. Eur J Pharmacol 243:227–234
Tallentire D, McRae G, Spedding M, Clark R, Vickery B (1996) Modulation of sexual behaviour in the rat by a potent and selective α 2-adrenoceptor agonist, delequamine (RS-15835–197). Br J Pharmacol 118:63–72
Flinders Sensitive Line of Rats
Daws LC, Overstreet DH (1999) Ontogeny of muscarinic cholinergic supersensitivity in the Flinders sensitive line rat. Physiol Biochem Behav 62:367–380
Dremencov E, Gispan-Herman I, Rosenstein M, Mendelman A, Overstrett DH, Zohar J, Yadid G (2004) The serotonindopamine interaction is critical for fast-onset action of antidepressant treatment: in vivo studies in an animal model of depression. Prog Neuropsychopharmacol Biol Psychiatry 28:141–147
Dremencov E, Newman ME, Kinor N, Blatman-Jan G, Schindler CJ, Overstreet DH, Yadid G (2005) Hyperfunctionality of serotonin-2C receptor mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 48:34–42
Ferreira-Nuño A, Overstreet DH, Morales Otat A, VelaźquesMoctezuma J (2002) Masculine sexual behavior features in the Flinders sensitive and resistant line rats. Behav Brain Res 128:113–119
King JA, Edwards E (1999) Early stress and genetic influences on hypothalamic-pituitary-adrenal axis functioning in adulthood. Horm Behav 36:79–85
King JA, Abend S, Edwards E (2001) Genetic predisposition and the development of posttraumatic stress disorder in an animal model. Biol Psychiatry 50:231–237
Lavi-Avnon Y, Yadid G, Overstreet DH, Weller A (2005) Abnormal patterns of maternal behavior in a genetic animal model of depression. Physiol Behav 84:607–615
Maayan R, Morad O, Dorfamn P, Overstreet DH, Weizman A, Yadid G (2005) The involvement of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks in an animal model of depression. Eur Neuropsychopharmacol 15:253–262
Overstreet DH (1986) Selective breeding for increases cholinergic function: development of a new animal model of depression. Biol Psychiatry 21:49–58
Overstreet DH (1993) The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev 17:51–68
Overstreet DH, Griebel G (2004) Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 497:49–51
Overstreet DH, Russell RW (1982) Selective breeding for dllsopropyl fluorophosphates-sensitivity: behavioural effects of cholinergic agonists and antagonists. Psychopharmacology (Berl) 78:150–155
Overstreet DH, Janowsky DS, Gillin JC, Shiromani PJ, Sutin EL (1986) Stress-induced immobility in rats with cholinergic hypersensitivity. Biol Psychiatry 21:657–664
Overstreet DH, Rezvani AH, Janowsky DS (1990) Impaired active avoidance responding in rats selectively bred for increased cholinergic function. Physiol Behav 47:787–788
Overstreet DH, Russell RW, Hay DA, Crocker AD (1992) Selective breeding for increased cholinergic function: biometrical genetic analysis of muscarinic responses. Neuropsychopharmacology 7:197–204
Overstreet DH, Pucilowski O, Rezvani AH, Janowsky DS (1995) Administration of antidepressants, diazepam and psychomotor stimulants further confirm the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology (Berl) 121:27–37
Overstreet DH, Keeney A, Hogg S (2004) Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. Eur J Pharmacol 492:195–201
Paré WP (2000) Investigatory behavior of a novel conspecific by Wistar Kyoto, Wistar and Sprague–Dawley rats. Brain Res Bull 53:759–765
Shayit M, Yadid G, Overstreet DH, Weller A (2003) 5-HT1A receptor subsensitivity in infancy and supersensitivity in adulthood in an animal model of depression. Brain Res 980:100–108
Shumake J, Edwards E, Gonzalez-Lima F (2003) Opposite metabolic changes in the habenula and ventral tegmental area of a genetic model of helpless behavior. Brain Res 963:274–281
Vasquez PAJ, Salmi P, Ahlenius S, Mathé AA (2000) Neuropeptide Y in brains of the Flinders Sensitive Line rat, a model of depression. Effects of electroconvulsive stimuli and damphetamine on peptide concentrations and locomotion. Behav Brain Res 111:115–123
Will CC, Aird F, Redel EE (2003) Selectively bred Wistar–Kyoto rats: an animal model of depression and hyper-responsiveness to antidepressants. Mol Psychiatry 8:925–932
Yadid G, Nakash R, Deri I, Tamar G, Kinor N, Gispan I, Zangen A (2000) Elucidation of the neurobiology of depression: insight from a novel genetic animal model. Prog Neurobiol 62:353–378
Genetically Altered Mice as Models of Depression
Calapai G, Crupi A, Firenzuoli F, Inferrera G, Ciliberto G, Parisi A, De Sarro G, Caputi AP (2001) Interleukin-6 involvement in antidepressant action of Hypericum perforatum. Pharmacopsychiatry 34(Suppl 1):S8–S10
Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Müller U, Aguet M, Babinet C, Shih JC (1995) Aggressive behavior and altered amounts of brain serotonin and epinephrine in mice lacking MAOA. Science 268:1763–1766
Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA (2002) cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 22:3262–3268
Cyran JF, Mombereau C (2004) In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9:326–357
Cyran JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA (2001) Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanisms of action of antidepressant drugs. J Pharmacol Exp Ther 298:651–657
Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and further needs. Trends Pharmacol Sci 23:238–245
El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeous JM (2001) Adenosine A 2A receptor antagonists are potential depressants: evidence based on pharmacology and A 2A receptor knockout mice. Br J Pharmacol 134:68–77
El Yacoubi M, Bouali S, Popa D, Naudon L, Leroux-Nicollet I, Hamon M, Costentin J, Adrien J, Vaugeois JM (2003) Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci U S A 100:6227–6232
Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, De Felipe C, Rupniak NM, Hunt SP, Jacquot C, Hamon M, Lanfumey L (2001) 5-Hydroxytryptamine1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 21:8188–8197
Grimsby J, Toth M, Chen K, Kumatawa T, Klaidman L, Adams JD, Karoum F, Gal J, Shih JC (1997) Increased stress response and β-phenylethylamine in MAOB deficient mice. Nat Genet 17:206–210
Holmes A, Hollon TR, Gleason TC, Liu Z, Dreiling J, Sibley DR, Crawley JN (2001) Behavioral characterization of dopamine receptor D5 null mutant mice. Behav Neurosci 115:1129–1144
Jaber M, Jones S, Giros B, Caron MG (1997) The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 12:629–633
Lijam N, Paylor R, McDonald MP, Crawley JN, Deng CX, Herrup K, Stevens KE, Maccaferri G, McBain CJ, Sussman DJ, Wynshaw-Boris A (1997) Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. Cell 90:895–905
MacQueen GM, Ramakrishnan K, Croll SD, Siuciak JA, Yu G, Young LT, Fahnestock M (2001) Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression. Behav Neurosci 115:1145–1153
Mayorga AJ, Dalvi A, Page ME, Zimov-Levinson S, Hen R, Lucki I (2001) Antidepressant-like behavioral effects in 5hydroxytryptamine1A and 5-hydroxytryptamine1B receptor mutant mice. J Pharmacol Exp Ther 298:1101–1107
Porsolt RD (2000) Animal models of depression: utility for transgenic research. Rev Neurosci 11:53–58
Sallinen J, Haapalinna A, MacDonald E, Viitamaa T, Lähdesmâki J, Rybnikova A, Pelto-Huikko M, Kobilka BK, Scheinin M (1999) General alteration of the á2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol Psychiatry 4:443–452
Stork O, Ji FY, Kaneko K, Stork S, Yoshinobu Y, Moriya T, Shibata S, Obata K (2000) Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65. Brain Res 865:45–58
Svenningsson P, Tzavara ET, Witkin JM, Flenberg AA, Nomikos GG, Greengard P (2002) Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A 99:3182–3187
Wei Q, Lu XY, Liu L, Schafer G, Shieh KR, Burke S, Robinson TE, Watson SJ, Seasholtz AF, Akil H (2004) Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc Natl Acad Sci U S A 101:11851–11856
Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Wang YM, Caron MG (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 3:465–471
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Kallman, M.J. (2015). Antidepressant Activity. In: Hock, F. (eds) Drug Discovery and Evaluation: Pharmacological Assays. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27728-3_31-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-27728-3_31-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27728-3
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences
Publish with us
Chapter history
-
Latest
Antidepressant Activity- Published:
- 18 May 2016
DOI: https://doi.org/10.1007/978-3-642-27728-3_31-2
-
Original
Antidepressant Activity- Published:
- 22 July 2015
DOI: https://doi.org/10.1007/978-3-642-27728-3_31-1